Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Other Non-Current Assets data on file, last reported at $1.4 million in Q3 2025.

• For the quarter ending Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2025 stood at $1.4 million (changed 0.0% YoY), and the FY2024 full-year result was $1.4 million, up 20.75% from the prior year.
• Other Non-Current Assets for Q3 2025 stood at $1.4 million, up from $463000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.4 million in Q3 2024 and bottomed at $115000.0 in Q1 2021.
• The 5-year median for Other Non-Current Assets is $1.3 million (2021), against an average of $1.1 million.
• The widest annual swing landed in 2021, when Other Non-Current Assets soared 1054.78%; it then tumbled 61.8% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then declined by 9.57% to $1.2 million in 2023, then rose by 20.75% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
• The last three Other Non-Current Assets figures came in at $1.4 million (Q3 2025), $463000.0 (Q1 2025), and $1.4 million (Q4 2024), per Business Quant data.

Peer Comparison